UK Government Health Agency Issued Final Guidelines Recommending Against Benlysta Coverage

In its final draft guidance the United Kingdom’s health watchdog National Institute for Health and Clinical Excellence (NICE) continues to recommend against coverage by the National Health Service of the recently approved Benlysta (belimumab) for lupus despite a cost-saving offer from the manufacturers. Please visit to sign a petition calling for NICE to reconsider its position. Read more from the British newspaper The Guardian.